1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to...
1. Median overall survival was longer in patients receiving steroid-only treatment for adverse events associated with immune response. 2. Patients...
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2....
1. In the pembrolizumab arm, distant metastasis-free survival was significantly improved and the risk of recurrence remained lower than the...
1. In comparison to vehicle-control, a greater proportion of patients using ruxolitinib achieved a reduction in facial Vitiligo Area Scoring...
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher...
1. Patients with dermatomyositis treated with intravenous immune globulin (IVIG) were more likely to see improvement in their disease severity...
Ipilimumab addition to nivolumab showed no significant clinical benefit in resected advanced stage melanoma There was no significant difference in...
1. Objective response rate was not significantly different in patients treated with stereotactic body radiotherapy compared to those without. 2....
1. By week 16, 28% of patients in dupilumab reported clear or almost clear skin (IGA 0-1) compared to 4%...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.